SOURCE-LINKED STUDY SUMMARY
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Abstract summarizedQuality not appraised
- What was studied
- A double-blind phase 2 trial compared weekly semaglutide with placebo in NASH-related compensated cirrhosis.
- Who / model studied
- Adults had biopsy-confirmed NASH-related cirrhosis and met the study's BMI threshold.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Semaglutide did not significantly improve fibrosis or NASH resolution versus placebo. Liver and kidney function remained stable, with no decompensation or deaths.
- Limitations & context
- The trial enrolled a relatively small group, and gastrointestinal adverse events were more frequent with semaglutide.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s2468-1253(23)00068-7